Literature DB >> 30807786

DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains.

María Hernández-Sánchez1, Ana Eugenia Rodríguez-Vicente2, Isabel González-Gascón Y Marín3, Miguel Quijada-Álamo2, Jesús María Hernández-Sánchez2, Marta Martín-Izquierdo2, José Ángel Hernández-Rivas3, Rocío Benito2, Jesús María Hernández-Rivas4.   

Abstract

The presence of chromosomal gains other than trisomy 12 suggesting a hyperdiploid karyotype is extremely rare in chronic lymphocytic leukemia (CLL) and is associated with a dismal prognosis. However, the genetic mechanisms and mutational background of these patients have not been fully explored. To improve our understanding of the genetic underpinnings of this subgroup of CLL, seven CLL patients with several chromosomal gains were sequenced using a next-generation sequencing (NGS)-targeted approach. The mutational status of 54 genes was evaluated using a custom-designed gene panel including recurrent mutated genes observed in CLL and widely associated with CLL pathogenesis. A total of 21 mutations were detected; TP53 (42.8%), ATM (28.5%), SF3B1 (28.5%), and BRAF (28.5%) were the most recurrently mutated genes. Of these mutations, 61.9% were detected in genes previously associated with a poor prognosis in CLL. Interestingly, five of the seven patients exhibited alterations in TP53 or ATM (deletion and/or mutation), genes involved in the DNA damage response (DDR), which could be related to a high genetic instability in this subgroup of patients. In conclusion, CLL patients with several chromosomal gains exhibit high genetic instability, with mutations in CLL driver genes and high-risk genetic alterations involving ATM and/or TP53 genes.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30807786     DOI: 10.1016/j.exphem.2019.02.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data.

Authors:  Adrián Mosquera Orgueira; Beatriz Antelo Rodríguez; José Ángel Díaz Arias; Marta Sonia González Pérez; José Luis Bello López
Journal:  Front Genet       Date:  2019-09-20       Impact factor: 4.599

2.  Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.

Authors:  Miguel Quijada-Álamo; Claudia Pérez-Carretero; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; Ana-Belén Herrero; Jesús-María Hernández-Sánchez; Marta Martín-Izquierdo; Sandra Santos-Mínguez; Mónica Del Rey; Teresa González; Araceli Rubio-Martínez; Alfonso García de Coca; Julio Dávila-Valls; José-Ángel Hernández-Rivas; Helen Parker; Jonathan C Strefford; Rocío Benito; José-Luis Ordóñez; Jesús-María Hernández-Rivas
Journal:  Clin Transl Med       Date:  2021-02

Review 3.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

4.  Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.

Authors:  José Luis Ordóñez; Jesús-María Hernández-Rivas; Miguel Quijada-Álamo; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; Claudia Pérez-Carretero; Alberto Rodríguez-Sánchez; Marta Martín-Izquierdo; Verónica Alonso-Pérez; Ignacio García-Tuñón; José María Bastida; María Jesús Vidal-Manceñido; Josefina Galende; Carlos Aguilar; José Antonio Queizán; Isabel González-Gascón Y Marín; José-Ángel Hernández-Rivas; Rocío Benito
Journal:  Blood Cancer J       Date:  2021-07-09       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.